Malignant Melanoma Archive - Seite 4 von 19 - IOZK

The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers

2018-09-26/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic Cancer /von 2018-09-26 / Cancers (Basel) 2018 Sep;10(10)

The Role of Oncolytic Viruses in the Treatment of Melanoma

2018-08-25/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-08-25 / Curr Oncol Rep 2018 08;20(10):80

Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)

2018-08-05/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-08-05 / BMJ Open 2018 08;8(8):e021701

Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients.

2018-06-04/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-06-04 / J Clin Oncol 36, 2018 (suppl; abstr 9525)

Molecular signatures associated with tumor-specific immune response in melanoma patients treated with dendritic cell-based immunotherapy

2018-03-30/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-30 / Oncotarget 2018 Mar;9(24):17014-17027

Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models

2018-03-26/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-26 / Oncoimmunology 2018;7(7):e1445457

Proteomic Identification of Heat Shock-Induced Danger Signals in a Melanoma Cell Lysate Used in Dendritic Cell-Based Cancer Immunotherapy

2018-03-18/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-18 / J Immunol Res 2018;2018:3982942

Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

2018-03-06/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-03-06 / J Immunother Cancer 2018 Mar;6(1):19

A prospective, randomized, blinded, placebo-controlled, phase IIb trial of an autologous tumor lysate + yeast cell wall particles (YCWP) + dendritic cells (DC) vaccine vs unloaded YCWP + DC and embedded phase I/IIa trial with tumor lysate particle only (TLPO) vaccine in stage III and stage IV (resected) melanoma to prevent recurrence.

2018-01-25/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-01-25 / J Clin Oncol 36, 2018 (suppl 5S; abstr TPS201)

An update on the relevance of vaccine research for the treatment of metastatic melanoma

2017-11-23/in Dendritic Cells, International Publications, Malignant Melanoma /von 2017-11-23 / Melanoma Manag 2017 Dec;4(4):203-215